Introduction
Invasive aspergillosis is a major cause of mortality in immunocompromised patients and therapeutic options remain less than optimal. Therefore, seeking a vaccine to induce protective antifungal immunity in immunocompromised patients is attractive. Efforts made in the development of an anti-Aspergillus vaccine have had only limited success [1, 2] . In previous studies, we showed that heatkilled yeast cells of Saccharomyces cerevisiae (HKY) has a benefi cial effect in protecting mice against experimental systemic aspergillosis [3], coccidioidomycosis [4] , candidiasis [5] and cryptococcosis [6] . Currently, our efforts have expanded to study the protective effects of cell-wall
Material and methods

Mice
Male, 5-week-old, CD-1 mice (Charles River Laboratories, Wilmington, MA) were used. Animals were caged with fi ve in each cage, and 10 mice comprised each experimental group. Acidifi ed water and sterile irradiated food were provided ad libitum . All animal experiments were done with the approval of the Institutional Animal Care and Use Committee of the California Institute for Medical Research.
Control vaccine preparation
A heat-killed S. cerevisiae (HKY) vaccine preparation was used for a positive control in all experiments. HKY vaccine was made as described previously [3, 4] and stored at 4 ° C until used. HKY was adjusted to 4 ϫ 10 8 cells/ml by hemacytometer counting prior to use.
Preparation of Candida mannan
Mannan was prepared according to our previous study [11] . Briefl y, Candida albicans serotype A strain was grown in semi-synthetic liquid medium containing 2% d -glucose, 0.3% (NH 4 ) 2 SO 4 , 0.1% MgSO 4 , 0.05% KH 2 PO 4 , 0.5% yeast autolysate and microelement solution for 4 days at 28 ° C. Cells were harvested by centrifugation, then washed twice with distilled water with centrifugation after each wash, then the cell pellet was freeze-dried. Mannoprotein was extracted from the biomass suspended in 0.2 M NaCl by autoclaving at 120 ° C 3 times for 1 h each time. The supernatant extracts were combined and mannoprotein was precipitated with ethanol, dialyzed against distilled water and freeze dried. The freeze dried mannoprotein was suspended in 2% KOH and heated for 1 h at 100 ° C. Insoluble residue was separated by centrifugation, and mannan was precipitated with Fehling reagent [12] . The sedimented mannan-copper complex was dissolved in 3M HCl, and added drop-wise to methanolacetic acid. The precipitated mannan was dissolved in distilled water, dialyzed and freeze dried. Mannan was analyzed for carbon, hydrogen, and nitrogen content using an EA 1108 device (Fisons Instruments, Crawley, UK).
Monosaccharide composition
Mannan was hydrolyzed with 2M trifl uoroacetic acid for 1 h at 120 ° C. Quantitative determination of neutral sugars was carried out in the form of their trifl uoroacetates through the use of gas chromatography on a Hewlett-Packard Model 5890 Series II chromatograph equipped with a PAS-1701 column (0.32 mm ϫ 25 m), a temperature program starting at 110ºC ramping to 125ºC at 2ºC/min followed by a second ramping to 165ºC at 20ºC/min and a fl ow rate of hydrogen of 20 cm 3 /min.
C. albicans mannan-protein conjugates
C. albicans mannan was conjugated to bovine serum albumin (BSA) (fraction V, MW ∼ 67,000; Sigma-Aldrich, St. Louis, MO) as described previously, by activating free hydroxyls with 1-cyano-4-dimethylaminopyridinium tetrafl uoroborate (Sigma-Aldrich) [13, 14] . To purify the conjugate from unconjugated moieties, a Sepharose CL-6B column (200 ϫ 1.5 cm, fl ow rate 0.2 mL/min; BioRad, Hercules, CA) in 0.1 M phosphate buffer, pH 7.5 was used. The separation process was monitored refractometrically (refractometer RI-101; Shodex, Tokyo, Japan) and by UV-VIS detection. Fractions containing conjugate were pooled, dialyzed against water and freeze-dried. The mannan content in the conjugate was determined by phenol-sulphuric assay using C. albicans mannan as the standard [15] . The protein content was measured by Coomassie Brilliant Blue G 250 (CBB G250; Sigma-Aldrich) assay with BSA as the standard [16] . Four batches of mannan (I, II, III, IV) were derived from C. albicans and the protein conjugation of BSA to mannan was done as described. Mannan and mannan-BSA samples were dissolved in saline.
Preparation of mannan fractions
Mannan ( ∼ 100 mg/run) was dissolved in 0.1 M phosphate buffer, pH 7.5 and fractionated by size exclusion chromatography using a Sepharose CL-6B column (200 ϫ 1.5 cm, fl ow rate 0.2 mL/min; BioRad) in 0.1 M phosphate buffer, pH 7.5. The effl uent was monitored refractometrically. The high molecular weight fractions, as well the low molecular weight fractions, were pooled, desalted and freeze-dried. After re-chromatography the molecular weights of both mannan fractions were estimated by high performance liquid chromatography (HPLC) analysis at ambient temperature with two columns (250 ϫ 8 mm) packed with Biospher GM 300 and GM 1000 (Tessek, Prague, Czech Republic). Aqueous NaNO 3 (0.1 M) solution was used as the mobile phase. A set of size standards of pullulans (Gearing Scientifi c, Polymer Lab. Ltd, Ashwell, UK) was used for the calibration of the HPLC system.
Vaccination
Mice were vaccinated subcutaneously using two dorsal sites (i.e., 100 μ l at each site for mannan antigen candidate; 75 μ l at each site for HKY), on the schedule of 28, 21, and 14 days before challenge [3] . HKY at 6 ϫ 10 7 yeasts/mouse was used as a positive control vaccine [3] and shamvaccinated negative controls received an equal volume of
Results
Profi le of mannans
The saccharide composition of mannans, as well as the percentage of saccharide and protein in mannan-BSA conjugates, are listed in Table 1 . As indicated, in each batch about 10% of the conjugate by weight is protein, so comparisons of vaccine (unconjugated vs. conjugated) doses on a weight basis means doses of the conjugates have about 10% less polysaccharide by weight. The primary saccharide present was mannose. Depending on the preparation, small amounts of glucose and galactose were also present ( Table 1 ). The HPLC profi le of unfractionated C. albicans mannan polymer illustrates the wide size dispersion of mannan molecules (Fig. 1) . Fractionation of the mannan, done by size exclusion chromatography, yielded two different molecular-sized fractions (with modes of 40 kDa and 500 kDa; Fig. 1 ). The conjugates of mannan fractions with BSA were prepared by the same protocol as for polymeric mannan-BSA conjugate. The total polysaccharide content of the conjugates constructed of mannan polymer, as well of the 40 kDa and 500 kDa mannan fractions, varied from 85.5 -92.9% and the protein varied from 7.1 -14.5%.
Low dose mannan vaccine studies
In the initial experiments we sought to determine whether vaccination of mice with preparations of unconjugated mannan or mannan-BSA, at doses of 0.003, 0.03, or 0.3 mg, would produce any signifi cant protective effect against systemic aspergillosis, and how these might be compared to the protection induced by HKY, which was used as a positive control. After 16 d of systemic infection with A. fumigatus , the HKY control prolonged survival, with 90% of the mice surviving in comparison to 40% survival of the PBS-vaccinated mice ( P ϭ 0.02). Vaccination with either the unconjugated mannan I ( Fig. 2A ) or II ( Fig. 3A) preparation at any dose did not result in signifi cant protective PBS. Mannan or mannan-BSA was given at doses of 0.003, 0.03, 0.3, 3, 12 or 24 mg (based on total weight), in 0.2 ml volume, in the various experiments.
Infection
Mice were infected with Aspergillus fumigatus strain 10AF conidia as described previously [17 -20] . Conidia were harvested with saline/0.05% Tween-80 from 5-to-7-day sporulated cultures grown on potato dextrose agar at 37 ° C. Inoculum viability was tested by plating 10-fold dilutions of conidia on SDA plates. The number of conidia was adjusted to 3.2 ϫ 10 7 conidia/ml. Each mouse received (6 -9.5) ϫ 10 6 viable conidia (depending on the experiment) in saline/Tween 80 given intravenously via a lateral tail vein as described previously [17 -20] .
Survival and tissue burdens
Mice were checked for survival daily. Sixteen days after infection, surviving mice were euthanatized by CO 2 anoxia. The brain and kidneys were removed aseptically and homogenized in 0.9% saline. Samples of 10-fold dilutions were plated on SDA with 50 mg of chloramphenicol per L. After culture for 48 h at 37 ° C, CFU were counted and log 10 CFU/organ determined [18 -22] . The lower limit of detection of the assay is 10 CFU/organ.
Statistics
Comparisons of survival were performed by log rank test. Fungal tissue burden was analyzed by Mann Whitney U test using GraphPad 3.0 for Windows. An arbitrary value of log 10 CFU ϭ 6 (a value higher than that from the organ of any mouse that survived) was assigned to data points missing due to the death of an animal after infection [22, 23] . This value represents the approximate CFU present in the organ just prior to death, and assures death is assigned a worse outcome than survival with any burden. Comparison of the mannan-BSA conjugates to the PBS control group showed that administration of 0.3 mg mannan I-BSA conjugate did not signifi cantly prolong survival, although 70% of mice survived through 16 days of infection ( Fig. 2B ). Vaccination with 0.3 mg mannan II-BSA provided a signifi cant protective effect ( P ϭ 0.004), with all mice surviving through 16 days of infection ( Fig. 3B ). Administration of 0.003 or 0.03 mg of mannan-BSA antigens did not protect mice challenged with Aspergillus ( P Ͼ 0.05). In comparison to unconjugated mannan I or II, the BSA conjugation to mannan I or II resulted in better protection at the 0.3 mg dose ( P Ͻ 0.05). The fungal burden of A. fumigatus remaining in the brain and kidneys of all surviving mice was determined after 16 days of infection. No dose of unconjugated mannan I or mannan II caused a signifi cant reduction of CFU in brain. Mice vaccinated with 0.3 mg of mannan I-BSA ( Fig. 2C ) or mannan II-BSA ( Fig. 3C ) had fewer CFU in brain compared to PBS ( P ϭ 0.06 or P ϭ 0.02, respectively). Vaccination with the lower two doses of the mannan-BSA conjugates did not cause CFU reduction in brain. In comparison to 0.3 mg of unconjugated mannan-II antigen, 0.3 mg of mannan II-BSA vaccination resulted a greater reduction of fungal burden in the brain ( P ϭ 0.009) ( Fig. 3C) .
A. fumigatus recovered from the kidneys (the target organ in this model) of HKY-vaccinated mice was less than in those from the PBS-vaccinated control group ( P ϭ 0.03, Fig. 2D or 3D ). Signifi cant reduction of CFU was found in the group vaccinated with 0.03 mg of mannan I ( P ϭ 0.04) ( Fig. 2D ). Mice vaccinated with 0.3 mg of mannan I-BSA nearly attained signifi cant reduction of CFU ( P ϭ 0.06); no differences from controls were found for the 0.003 mg dose (Fig. 2D ). In the kidneys of mannan II vaccinated mice, signifi cant reduction of CFU was observed in the groups vaccinated with 0.3 mg of mannan II or mannan II-BSA (both P Ͻ 0.0001) (Fig. 3D) ; lower dosages of the mannan II preparations did not cause a signifi cant reduction in fungal burden in the kidneys.
Vaccine dose-escalation studies
In the next study we sought to determine whether higher doses of the vaccines would allow us to observe an improved effect of mannan-or mannan-BSA-vaccination against systemic Aspergillus infection. Therefore, we escalated the dosage of mannan III and mannan III-BSA (new lot preparations) given to each mouse, and gave 0.3, 3 or 12 mg/ dose for vaccination. After 16 days of infection, the HKY control had signifi cantly prolonged survival and 80% of the mice survived ( P ϭ 0.004) ( Fig. 4A and 4B ). In comparison to the PBS controls, vaccination with 12 mg of unconjugated mannan III resulted in signifi cant protective effi cacy ( P ϭ 0.006); however, lower doses did not show signifi cant protective effects compared to the PBS controls ( P Ͼ 0.05) ( Fig. 4A ).
All doses of mannan III-BSA signifi cantly prolonged mouse survival (all P Ͻ 0.005, Fig. 4B) ; however, the doseresponse with mannan III-BSA was fl at at these three doses, suggesting a peak in the dose-response curve. In comparison to the same dose of unconjugated mannan III, the mannan III -BSA conjugate vaccine resulted in enhanced protection at doses of 0.3 or 3 mg ( P Ͻ 0.05), whereas the 12 mg doses were equivalent ( P Ͼ 0.05, Fig.  4A and 4B).
Fungal load was assessed in the brain and kidneys of all surviving mice after 16 days of infection. No signifi cant reduction in burden of A. fumigatus was observed in either brain or kidneys of mice vaccinated with any dose of unconjugated mannan III ( P Ͼ 0.05) ( Fig. 4C and 4D) . Thus, the borderline protective effects of lower doses of unconjugated mannan seen with preparations I and II (lack of survival effect but some reduction of organ burdens) were not substantiated in these studies.
Mice vaccinated with any dose of the mannan III-BSA conjugate had signifi cantly fewer CFU in brain or kidneys versus the PBS controls (all P Ͻ 0.05, Fig. 4C and 4D ). CFU were not detectable in a number of individual brains from mice given HKY, or the 3 or 12 mg mannan III-BSA regimens (Fig. 4C) ; no mice given HKY and only 1 or 2 mice given 3 or 12 mg of mannan III-BSA were free of detectable kidney burden. In comparison to equivalent doses of unconjugated mannan III, doses of 0.3 mg and 3 mg mannan III-BSA showed signifi cantly greater reduction of fungal burden in brain or kidneys ( P Ͻ 0.05); the CFU recovered from mice vaccinated with 12 mg of mannan III or mannan III -BSA were equivalent in both organs ( Fig. 4C and 4D) . In a replicate experiment, we continued to explore the maximum dose of unconjugated mannan that would confer protection and also repeated the doses of 0.3 mg and 3 mg of mannan-BSA. After 14 days of infection, administration of HKY again prolonged survival and 90% of the mice survived compared to 30% survival for PBS controls ( P ϭ 0.01). In comparison to the PBS controls, vaccination with 12 mg of unconjugated mannan IV again resulted in signifi cant protective effi cacy ( P ϭ 0.008) (Fig. 5A) . In contrast, a vaccine dose of 24 mg of mannan IV did not result in signifi cant protective effects ( P Ͼ 0.05) ( Fig. 5A ) and vaccination with mannan IV at 12 mg was superior to 24 mg ( P ϭ 0.03). Compared to the PBS control group, both doses of mannan IV-BSA (0.3 mg or 3 mg) prolonged survival ( P ϭ 0.008, P ϭ 0.001, respectively, Fig. 5B ).
After 14 days of infection, fungal burden in the brains of HKY-vaccinated mice was signifi cantly lower compared to PBS controls ( P ϭ 0.0005, Fig. 5C ). Mannan IV at 12 mg now also caused a signifi cant reduction of CFU in comparison to the PBS controls ( P ϭ 0.0003), or versus mannan IV at 24 mg ( P ϭ 0.02). Mice given either dose of mannan IV-BSA had signifi cantly fewer CFU in brain compared to PBS controls ( P Ͻ 0.0001). Interestingly, 9 mice vaccinated with 12 mg of mannan IV-BSA, 9 mice vaccinated with 0.3 mg of mannan IV-BSA, and all 10 mice vaccinated with 3 mg mannan IV-BSA were free of detectable infection in the brain (Fig. 5C) .
CFU in the kidneys of HKY-vaccinated mice were lower than those of the PBS-vaccinated control group ( P ϭ 0.001, Fig. 5D ); now signifi cantly fewer CFU also was observed in kidneys from mice vaccinated with 12 mg of unconjugated mannan IV ( P ϭ 0.001). Thus, survival advantage conferred by unconjugated mannan at 12 mg was confi rmed, and with this preparation, signifi cant reduction of fungal burden was also shown. , an arbitrary value of 6 was assigned to mice that died from 10AF infection [22, 23] , so that death was assigned a worse outcome than survival with any burden. A value of zero indicates the CFU was below the detectable limit. The 0.3 or 3 mg doses of mannan IV-BSA caused signifi cant reduction of CFU compared to PBS controls (both P Ͻ 0.0001). Mice vaccinated with mannan IV-BSA at 3 mg had signifi cantly fewer CFU recovered from the kidneys than did those from any other vaccine regimen, including HKY (all P Ͻ 0.01, Fig. 5D ). In comparison, HKY, 0.3 mg of mannan IV -BSA, 12 mg and 24 mg of mannan IV were equivalent in reduction of CFU in kidney ( P Ͼ 0.05).
Effect of molecular size of mannan
To determine if mannan-induced protection was related to the molecular size of the antigen preparations, we tested the protective effects of two fractions of BSA-conjugated mannan (40 kDa and 500 kDa) obtained by size exclusion chromatography, as well as an unfractionated, total mannan conjugated to BSA. As expected, the HKY-positive control prolonged survival and 90% of the mice survived compared to 10% survival for PBS controls ( P ϭ 0.0005) (Fig. 6) . In comparison to the PBS controls, vaccination with 0.3 or 3 mg of 500 kDa mannan-BSA resulted in signifi cant protective effi cacy ( P ϭ 0.01, P ϭ 0.0005), with 70% or 90% of the mice surviving in each group, respectively (Fig. 6B ). However, neither the 0.03 mg of 500 kDa mannan-BSA nor any dose of 40 kDa mannan-BSA resulted in signifi cant protective effects ( P Ͼ 0.05) ( Fig. 6A and 6B) . Confi rming the results in the other in vivo experiments, administration of 0.3 or 3 mg total mannan-BSA prolonged survival compared to the PBS control group ( P ϭ 0.0003, P Ͻ 0.0001, respectively). Interestingly, after vaccination with 3 mg of total mannan-BSA all mice survived the infection. However, the lower dose of 0.03 mg total mannan-BSA was not protective for mice ( P Ͼ 0.05) (Fig. 6C ). Comparing the 500 kDa mannan-BSA fraction at 0.3 mg or 3 mg doses to 40 kDa mannan-BSA fraction at the equivalent doses showed the 500 kDa fraction to be more effective at the 3 mg dose ( P ϭ 0.01) and nearly so at the 0.3 mg dose ( P ϭ 0.07) ( Fig. 6A and 6B ) . Similarly, total mannan-BSA showed better protection of mice at doses of 0.3 or 3 mg than did the 40 kDa mannan-BSA fraction (both P Ͻ 0.01, Fig. 6A and  6C) . Total mannan-BSA or 500 kDa mannan-BSA at 3 mg were the most effective dosages, with survival equal to or greater than that provided by HKY. CFU in the brains of HKY-vaccinated mice were reduced compared to PBS controls ( P ϭ 0.0002) (Fig. 6D) . Mice vaccinated with 500 kDa mannan-BSA at 0.3 mg or 3 mg had fewer CFU compared to the PBS controls ( P ϭ 0.01, P ϭ 0.0002, respectively). However, 0.03 mg of 500 kDa mannan-BSA and all doses of 40 kDa mannan-BSA did not cause reduction of CFU in the brain (all P Ͼ 0.05). Mice vaccinated with 0.3 mg or 3 mg of total mannan-BSA also had fewer CFU in brains compared to PBS controls ( P ϭ 0.0002, P Ͻ 0.0001, respectively), whereas 0.03 mg of total mannan-BSA did not show any effect on reduction of CFU (Fig. 6D ). In addition, 0.3 or 3 mg of 500 kDa mannan-BSA or total mannan -BSA was equivalent to HKY in the reduction of fungal load in brain ( P Ͼ 0.05) (Fig. 6D) .
In comparison to the PBS control, signifi cant reduction of CFU was observed in kidneys of mice vaccinated with 0.3 mg or 3 mg of 500 kDa mannan -BSA ( P ϭ 0.01, P ϭ 0.002, respectively) ( Fig. 6E) . Total mannan-BSA at 0.3 mg or 3 mg dose also reduced CFU in kidneys compared to PBS controls (both P Ͻ 0.0001). However, none of the 40 kDa doses of mannan-BSA caused signifi cant reduction of CFU in kidneys. In comparison to HKY, 0.3 mg or 3 mg of 500 kDa mannan-BSA or total mannan -BSA were equivalent ( P Ͼ 0.05) (Fig. 6E ). Mice vaccinated with the 500 kDa mannan-BSA fraction at 3 mg had fewer CFU compared to those given the 40 kDa mannan-BSA at 3 mg ( P ϭ 0.02, Fig. 6E ). Total mannan-BSA at doses of 0.3 or 3 mg showed better effi cacy in reducing fungal load than did equivalent doses of the 40 kDa mannan-BSA fraction (all P Ͻ 0.01) (Fig. 6E ).
Discussion
The cross-protection we have found against four fungal pathogens offered by HKY led to our interest in what the cross-protective components might be. Most recent vaccine efforts have been targeting polysaccharide components as fungal vaccines. Several conjugated glycan vaccines have shown protection in experimental models of candidiasis, cryptococcosis and aspergillosis [24 -27] . One of the candidates, mannan extracted from the cell wall of C. albicans yeast cells, exhibited a protective effect in mice against candidiasis [25] . Our current study aimed to explore the possibility of using mannan as a vaccine that would be cross-protective against systemic murine aspergillosis. The model used mimics disseminated aspergillosis as seen in humans, where disseminated hematogenous infection arises from a pulmonary (sometimes clinically inapparent) or other focal site. One projected use of a vaccine against aspergillosis is that of immunizing the individual prior to their increased risk of infection due to immunosuppressive therapy. Therefore, we chose to use the systemic model of aspergillosis as a screening tool, with the thought that if the preparations were unable to induce protection in immunocompetent mice they would be unlikely to be useful in the induction of immunity prior to an individual becoming immunocompromised or in at risk patients that are not immunocompromised.
Mannan is a major polysaccharide constituent of the yeast cell wall and represents a principal surface antigen. We showed that the mannan derived from the cell wall of C. albicans yeast cells protected mice from A. fumigatus infection. Mannan-induced protection was dose-dependent. Unconjugated mannan alone showed positive effects only when used in a relatively high dose (12 mg). Pure glycans are usually poorly immunogenic [28, 29] . Therefore, it may require a large amount to boost the immune response and induce protection. Previous studies in the literature with glycan conjugates have utilized adjuvants as part of the vaccination regimen. Because most adjuvants did not appear benefi cial to the HKY protective effect [3], possibly because the yeast cell intrinsically contains adjuvant materials, our present studies did not explore adjuvants. The results we report here have not required an adjuvant; thus, the larger doses of conjugates we have used, in comparison to those in the literature, to demonstrate a protective effect, may also be reduced if adjuvants would boost the responses to our reagents.
Compared to mannan alone, the presence of BSA conjugated to the mannan improved the protective effi ciency against systemic aspergillosis. A dose as low as 0.3 mg BSA-conjugated mannan induced protection in mice against systemic Aspergillus infection, a dose which is 40 times lower than that of unconjugated mannan needed to induce signifi cant protection. Thus, mice were more resistant to Aspergillus infection when vaccinated with conjugated mannan, a result consistent with previous studies using mannan as a vaccine against candidiasis [25, 28, 29] .
Mannan may induce protective levels of antibodies thereby enhancing host resistance to fungal infection [8, 25, 28] . The capacity of mannan to induce a suffi cient level of antibody response for protection may also be related to the formulation of mannan used for vaccination [25, 28] . Our preliminary studies on the role of humoral immunity as a mechanism of mannan vaccine-induced immunity gave confl icting results. Although immunization with mannan or mannan-BSA, with the vaccination regimens described, induced antibodies detectable by ELISA [8,30 -32] there was no correlation between protective Although the mechanism underlying the heterologous protection induced by a C. albicansderived mannan against aspergillosis is not yet known, cross-protection by glycan vaccine preparations from different species has been shown in several studies [26, 33, 34] . A vaccine candidate composed of laminarin ( β -1 → 3 glucan) conjugated with a modifi ed diphtheria toxoid (CRM-197) induced antibody-mediated protection against candidiasis, cryptococcosis, and aspergillosis, suggesting that it is possible to immunize with a crossreacting antigen against even evolutionarily distant infectious agents [34] . The BSA-conjugated mannan we used induced a broad-spectrum protection against aspergillosis in these studies and against coccidioidomycosis in other studies [35] , indicating that mannan is a promising vaccine candidate. The full picture of the protective response resulting from mannan vaccination needs further elucidation. It is possible that the anti-mannan antibody produced by vaccination with Candida mannan inhibits the adherence of A. fumigatus to endothelial cells and/or reduces fungal hyphal growth. Consistent with this notion, it was shown that antibody induced by the laminarin-CRM vaccine could bind to A. fumigatus hyphae and inhibit hyphal growth [26] . It is also possible that mannan-induced antibody binds to mannan associated with some superficial or secreted cell wall protein components such as adhesins, or enzymes involved in cell wall organization, and thereby sterically inhibits adherence, or hyphal growth, of Aspergillus . Mannan-induced immunoprotection may also involve T-cell mediated immunity. It was shown that binding of C. albicans mannan with the mannose receptor was the main pathway triggering a Th17 cell response to C. albicans , thus inducing IL-17 cytokine production [36] . IL-17 has emerged as one of the most important infl ammatory cytokines for the defense against human fungal pathogens [36] . Extensive study of the mannan-induced cellular response is warranted and would contribute to understanding the nature of mannan-induced protection.
We found that BSA-conjugated 500 kDa mannan was more protective against aspergillosis than was BSAconjugated 40 kDa mannan. The length of the mannan polymer may play a key role in determining the outcome of immunomodulation and vaccination. It is well established that the immunomodulatory effects of glycans are infl uenced by the degree of branching, polymer length and tertiary structure [2,37 -39] . This could be related to epitope exposure, ability to stimulate dendritic (or other antigenpresenting) cells, or duration of stimulation (as opposed to clearance) at the vaccine site. Our fi ndings are in contrast to studies of Candida mannan in a conjugate vaccine versus candidiasis, which concluded oligosaccharides (chains with as few as 2 -3 sugars) were optimal [24, 25, 28, 38] . However, in the latter studies the oligosaccharide conjugate vaccines were administered with an adjuvant (e.g., alum). In contrast, no adjuvant was used in our studies. The use of an adjuvant may improve the effi cacy of the BSAconjugated 40 kDa mannan. In studies of mannans as vaccines against experimental coccidioidomycosis (unpublished), we have found again that conjugated mannan is superior to unconjugated in producing a signifi cant protective effect, and a difference, from the results in aspergillosis, that both 500 kDa BSA-conjugated mannan and BSA-conjugated 40 kDa mannan were protective, although the 500 kDa preparation appeared more optimal, as noted in the present studies.
Although the structure and composition of mannan may vary with species [39], our in vivo studies indicated that Aspergillus and Candida mannan may share glycan epitopes that lead to cross-protection. These studies implicate mannan as a major candidate to explain the protection against infection with four different fungal species provided by immunization with HKY [2 -6].
C. albicans cell-wall mannan is a branched polymer of mannopyranose. It consists of an α -1,6-poly-mannopyranosyl backbone, to which manno-oligosaccharide side chains of variable lengths are attached. Apart from a number of mannopyranosyl units, the side chains differ also by glycosidic linkages connecting the units ( α -1,2; α -1,3; β -1,2) [40] . The side chain of phosphorylated β -(1,2)-linked manno-oligosaccharides is recognized as the primary epitope [41] that may induce humoral responses [42] . However, in the Aspergillus cell wall, galactofuran side chains have been identifi ed as immunodominant and the α -(1,2; 1,6) mannan core was not antigenic [43] . Identifying cell wall ligands or epitopes that are responsible for specifi c immune recognition is critical to understanding the mechanism of cross-reactivity between these fungi, and this information would provide insight for fungal vaccine development.
In summary, in this study we have provided evidence that mannan derived from C. albicans , used as a vaccine, cross-protects mice against systemic aspergillosis. Furthermore, conjugated mannan showed increased potential as a vaccine candidate. The activities of all four batches of mannan (mannan I -IV) suggested that the majority mannose component is more important for inducing protection than are the varying lesser amount of galactose or glucose components in the preparation. It will be of interest in future studies to determine whether mannan conjugated with a specifi c Aspergillus protein has further enhanced potency as a vaccine against Aspergillus .
